A PhaseⅡa, Placebo Parallel Control, Central Randomized, Double Blind, Dosage Exploring and Multi-Center Study to Evaluate the Efficacy and Safety of Ginsenoside H Dripping Pills in Patients With Advanced NSCLC (Syndrome Of Qi-Deficiency)
Latest Information Update: 10 Dec 2018
At a glance
- Drugs Ginsenoside Rh2 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Tasly Pharmaceutical Group
- 19 Mar 2017 Status changed from not yet recruiting to recruiting.
- 29 Mar 2016 New trial record